A method for producing bacterial outer membrane vesicles by bacterial fermentation
By regulating glucose concentration in two stages during bacterial fermentation, the problems of low yield and high nucleic acid residues in OMV vaccine production are solved, and efficient OMV yield improvement and process simplification are achieved, which is suitable for large-scale production.
Patent Information
- Application Number
- CN202410969543.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-18
AI Technical Summary
The existing OMV vaccine production process has problems such as low yield, high nucleic acid residues of by-products, and high process complexity, which limits the commercial development of OMV vaccines.
During the bacterial fermentation process, the glucose concentration in the fermentation broth is controlled by two-stage method. The high concentration is maintained before the end of the logarithmic growth phase of the bacteria, and then it is significantly reduced. The glucose concentration in the fermentation broth is controlled by controlling the flow plus glucose concentration and pump speed. Avoid the adverse effects of high sugar environment on bacteria.
It significantly increases the yield of bacterial outer membrane vesicles, reduces nucleic acid residues by-products, simplifies the process flow, and facilitates large-scale production.
Smart Images

Figure CN118497089B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the fields of fermentation engineering and biopharmaceuticals, and in particular to a method for producing bacterial outer membrane vesicles by bacterial fermentation, which comprises performing two-stage sugar supplementation at different stages of bacterial growth, thereby significantly increasing the yield of naturally secreted bacterial outer membrane vesicles (OMVs) and reducing the residual nucleic acid of byproducts. Background Art
[0002] OMV (outer membrane vesicle) is a nanoparticle produced by Gram-negative bacteria, which is highly immunogenic, non-infectious and non-replicative, and can be used for vaccine production. By adding heterologous antigens to OMV, the antigen expression does not change the characteristics of OMV, and the application of OMV as a vaccine component can be expanded to establish an OMV-based vaccine platform. However, not all Gram-negative bacteria are suitable for OMV vaccine production because the pathogens are highly pathogenic, grow slowly, have complex culture requirements, and have low OMV yields.
[0003] Neisseria meningitidis is a pathogen that infects different parts of the human host, causing acute meningitis and sepsis, with a high mortality rate, especially in infants and young children. There are different pathogenic isolates of Neisseria meningitidis, of which serotypes B and C cause most infections in industrialized areas, while types A and C are dominant in less developed areas. The development of safe vaccines based on serotype B capsular polysaccharides is complicated because the same structure exists in the human host, resulting in poor immunogenicity and the risk of inducing autoimmunity. Neisseria meningitidis secretes OMVs, and the outer membrane porin (PorA) is the main protective antigen, but it varies greatly among different strains. The coverage of the vaccine can be improved by superimposing other antigens, such as fHbp, FetA or supplementing with multiple different types of PorA. OMV vaccines have successfully controlled the outbreak of serotype B meningococcal disease. Currently, the most famous OMV-based vaccine is Bexsero, a vaccine for serotype B meningitis developed by GlaxoSmithKline, which is approved for infants over two months old and brings GSK annual sales of 390 million pounds.
[0004] At present, the main production processes of OMV include dOMV (detergent OMV), which adds detergent to remove lipopolysaccharide with strong endotoxic activity on the surface of OMV. The disadvantage is that the detergent deoxycholate is an animal-derived component, and the OMV produced by this method tends to aggregate, and the detergent is not completely removed during the purification process; eOMV (EDTA OMV), which uses the chelating agent EDTA to induce the production of OMV. The disadvantage is that the fermentation broth needs to be concentrated and the buffer solution needs to be replaced. The process complexity is increased due to the introduction of additional components; other methods for producing OMV, such as using culture media containing animal-derived components (tyrosine), using hazardous chemicals (such as phenol) to inactivate bacteria, using excessive mechanical stirring to release or homogenize bacteria, using toxic preservatives (such as thimerosal), using ultracentrifugation, etc., all complicate subsequent processing and limit the scale of production.
[0005] Genetic modification can develop spontaneously released OMVs (sOMVs). Compared with other OMV production methods such as dOMV and eOMV, sOMVs are naturally secreted vesicles that do not tend to aggregate. At the same time, the outer membrane vesicles retain protective lipoproteins to provide a wider range of immunogenicity, making them more suitable for development as vaccine products. However, the low yield of OMVs is an important factor preventing their commercialization. In order to increase the yield of OMVs, Gino JE Baar (Genome biology vol. 8,7 (2007): R136.doi:10.1186 / gb-2007-8-7-r136) proposed that the introduction of pure oxygen and cysteine depletion during the fermentation process can increase the yield of OMVs by fermenting for more than 24-140 hours, but the yield increase is limited. Matthias JH Gerritzen (Vaccine, Volume 37, Issue 47, 2019, Pages 6978-6986, ISSN 0264-410X) used cysteine depletion and other methods to increase the yield of sOMV to 7×10 14 About pcs / L.
[0006] In the traditional fermentation process, glucose is added in excess at one time or at a constant rate. However, the applicant found that the excessive addition of glucose at one time is not conducive to the early growth of the strain and the OMV production in the later stage. In addition, after the strain enters the stable period, the metabolism weakens and the sugar consumption decreases. If the constant rate is added, it will inevitably lead to glucose accumulation, accelerate bacterial aging, and reduce OMV production. In addition, excessive glucose in the fermentation broth will also make the fermentation broth viscous, which is not conducive to downstream purification.
[0007] Therefore, how to increase OMV production and how to increase OMV production by developing efficient fermentation process methods while reducing residual nucleic acid byproducts are technical issues that need to be urgently addressed in the commercial development of OMV vaccine products. Summary of the invention
[0008] The purpose of the present invention is to provide a method for producing bacterial outer membrane vesicles by bacterial fermentation, specifically, regulating the glucose concentration in the fermentation broth in two stages during the fermentation process, maintaining a high glucose concentration in the fermentation broth before the end of the bacterial logarithmic growth phase, and significantly reducing the glucose concentration in the fermentation broth after the end of the bacterial logarithmic growth phase. The method provided by the present invention significantly increases the yield of bacterial outer membrane vesicles.
[0009] "Outer membrane vesicles (OMV)" are cell wall membrane bubble-like particles spontaneously released to the outside of the cell by Gram-negative or Gram-positive bacteria, also known as natural outer membrane vesicles. The outer membrane vesicles referred to in the present invention can be produced by natural bacteria or by bacteria that have been genetically engineered to exhibit an excessive bubbling phenotype, wherein the excessive bubbling phenotype refers to the budding of a large number of outer membranes due to genetic modification, thereby achieving increased OMV production.
[0010] Therefore, the present invention provides a method for producing bacterial outer membrane vesicles by bacterial fermentation, comprising:
[0011] a) during the fermentation period from the start of bacterial fermentation to the end of the bacterial logarithmic growth phase, the glucose concentration in the fermentation broth is maintained at 2 g / L-5 g / L;
[0012] b) during the fermentation after the end of the bacterial logarithmic growth phase, reducing the glucose concentration in the fermentation broth by at least 50%; and wherein the glucose concentration in the fermentation broth is maintained at at least 0.1 g / L.
[0013] In some embodiments, step b) reduces the glucose concentration in the fermentation broth by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%.
[0014] In some embodiments, in step b), the glucose concentration in the fermentation broth is maintained at 0.1 g / L-1.5 g / L.
[0015] In some embodiments, in step a), the glucose concentration in the fermentation broth is maintained at 3.5 g / L-5 g / L; and in step b), the glucose concentration in the fermentation broth is maintained at 0.1 g / L-1.5 g / L.
[0016] "Fermentation broth" includes a culture medium used for fermentation and bacteria grown therein. The "culture medium" described in the present invention refers to any culture medium suitable for the growth and proliferation of bacteria such as meningococcal strain MC58 or meningococcal strain MC58ΔrmpM with knockout rmpM gene and / or production of OMVs, including but not limited to TSB culture medium, LB culture medium, and casein culture medium.
[0017] The "glucose concentration in the fermentation broth" refers to the glucose concentration actually present or measured during the fermentation process, and is also the glucose concentration remaining in the fermentation broth after the glucose added to the fermentation tank / liquid during the fermentation process is consumed by the bacteria.
[0018] The "glucose concentration in the fermentation broth" can be changed by adjusting and controlling the pump speed of the peristaltic pump for adding glucose and / or the glucose concentration added. In some embodiments, glucose is added in the form of feeding during the fermentation process, and the glucose concentration in the fermentation broth is regulated by regulating the glucose concentration of the feeding and / or regulating the pump speed of the peristaltic pump for adding glucose.
[0019] "Bacterial logarithmic growth phase" refers to when a microorganism, such as bacteria, is cultured in a closed system. After a certain stage of growth, the growth rate of the microorganism reaches a maximum, and the logarithmic growth phase is entered; during the logarithmic growth phase, microorganisms, such as bacteria, increase in geometric progression. The logarithmic growth phase of microorganisms, such as bacteria, can be determined by plotting a growth curve of the amount of bacteria (such as OD value) relative to time. Usually, the growth curve of the logarithmic growth phase of bacteria is a straight line with a certain slope. By plotting the growth curve, those skilled in the art can easily determine the beginning and end of the logarithmic growth phase. After the end of the logarithmic growth phase, the bacteria will continue to grow / proliferate at a reduced rate for a period of time until the growth stagnates or the bacteria die.
[0020] In some embodiments, the amount of bacteria can be measured every 1-2 hours during fermentation to draw a growth curve and determine the growth phase of the bacteria. In some embodiments, the logarithmic growth phase of Neisseria meningitidis is 2h-8h from the start of fermentation.
[0021] The two-stage sugar control used in the present invention refers to the addition of glucose during the fermentation culture process, and the glucose in the fermentation tank liquid is in different concentration ranges in the two stages of bacterial growth by adjusting the pump speed of the peristaltic pump for adding glucose. Specifically, before the end of the logarithmic growth phase of the fermented bacteria, the glucose in the fermentation liquid is controlled at a higher concentration to meet the carbon source required for bacterial growth. After the end of the logarithmic growth phase of the fermented bacteria, the glucose in the fermentation liquid is controlled at a lower concentration to adapt to the continued growth of the bacteria, avoid the adverse effects of high-concentration glucose on the bacteria, and reduce the damage of high-concentration glucose to the bacteria.
[0022] In some embodiments, samples are taken at regular intervals (e.g., every 1-2 hours) to measure the amount of bacteria during the fermentation process. When the bacterial OD value of the fermentation broth decreases by 0.3 or more compared with the previous time point (or the highest OD value), the fermentation is stopped and the target product OMV is harvested.
[0023] In some embodiments, the bacterial fermentation is carried out in a fermenter. The fermenter volume can be about 1L to about 1000L.
[0024] In some embodiments, before bacterial fermentation begins, the method further comprises one, two or three of the following stages: plate activation of bacteria, shake flask culture, and seed tank culture.
[0025] In some embodiments, when the volume of the fermenter is below 150 L, before the bacterial fermentation begins, the method further comprises a plate activation bacteria stage and a shake flask culture stage.
[0026] In some embodiments, when the volume of the fermenter exceeds 150 L, before the bacterial fermentation begins, the method further comprises a plate activation bacteria stage, a shake flask culture stage, and a seed tank culture stage.
[0027] In some embodiments, during the fermentation process, the temperature is controlled at 33-39° C., the pH is 6.5-8, the air volume is 0.4-2 vvm, and the dissolved oxygen is 10%-60%.
[0028] In some embodiments, the culture medium used in the fermentation is TSB medium or LB medium, and the volume of the culture medium in the fermentor is 40%-80% of the volume of the fermentor.
[0029] In some embodiments, at the beginning of fermentation, the OD value of the bacteria in the fermentation broth is 0.05-0.3.
[0030] In some embodiments, the glucose concentration and / or bacterial OD value in the fermentation broth is measured every 1-2 hours during the fermentation period.
[0031] In some embodiments, based on the detected glucose concentration in the fermentation broth, the desired glucose concentration in the fermentation broth is maintained by adjusting the glucose concentration of the feed and / or adjusting the pumping speed of the peristaltic pump for feeding glucose.
[0032] In some embodiments, when the measured bacterial OD value of the fermentation broth decreases by 0.3 or more compared with the measured highest OD value, the fermentation is stopped and the bacterial outer membrane vesicles are harvested.
[0033] In some embodiments, the fermentation time from the start of bacterial fermentation to the end of the bacterial logarithmic growth phase is about 8 hours.
[0034] In some embodiments, the fermentation is stopped at about 16 hours from the start of bacterial fermentation, and the bacterial outer membrane vesicles are harvested.
[0035] In some embodiments, the bacteria is selected from Gram-negative bacteria. In some embodiments, the bacteria is meningococcus. In some embodiments, the bacteria is meningococcus MC58 or meningococcus MC58 that does not express the rmpM gene.
[0036] In the previous OMV fermentation, glucose was added to the culture medium once at the beginning of the fermentation to ensure the growth of the strain throughout the fermentation process. However, the one-time excessive addition of glucose will inevitably cause the strain to be in a high-sugar environment all the time, causing the bacteria to accelerate aging, OD reduction, and increased nucleic acid residues. The present invention performs two-stage gradient sugar supplementation at different stages of bacterial growth, so that the glucose in the fermentation broth is maintained at an optimal concentration, slowing down the old lysis of the bacteria (OD reduction, increased nucleic acid residues), greatly improving the yield of naturally secreted OMVs, and reducing byproduct nucleic acid residues. Utilizing the two-stage gradient sugar supplementation process provided by the present invention, after the process is amplified, the various indicators of OMV are stable, which is conducive to large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 . Fermentation process curves of different sugar supplementation strategies in a 1L fermenter.
[0038] Figure 2 . Fermentation process curve of 5L fermenter.
[0039] Figure 3 . NTA detection of OMV particle concentration under 5L fermenter conditions (diluted 10,000 times).
[0040] Figure 4 . Fermentation process curve of 5L fermenter.
[0041] Figure 5 . NTA detection of OMV particle concentration under 5L fermenter conditions (diluted 10,000 times).
[0042] Figure 6 . Fermentation process curve of 150L fermenter.
[0043] Figure 7 . NTA detection of OMV particle concentration under 150L fermenter conditions (diluted 10,000 times). DETAILED DESCRIPTION
[0044] In the embodiments of the present invention, natural meningococcal strain MC58 (purchased from ATCC, BAA-335™) or meningococcal strains that do not express the rmpM gene (including MC58ΔrmpM, obtained by knocking out the rmpM gene using gene editing methods such as homologous recombination on the MC58 strain) are used only to illustrate the invention, and are not used to limit the scope of the invention. It is obvious that various modifications and changes can be made to the present invention without departing from the essence of the present invention, and such modifications and changes are also within the scope of the present invention. The technical solution of the present invention can be used to guide the production of OMVs of other Gram-negative bacteria.
[0045] Example 1, fermentation culture steps of Neisseria meningitidis
[0046] 1.1 Plate activation of bacterial strains
[0047] Take the frozen glycerol tube of Neisseria meningitidis MC58ΔrmpM from the -80° freezer, spread the bacteria in the glycerol tube on a GC agar medium (OXOID) plate in a biological safety cabinet (Thermo), and culture in a controlled carbon dioxide incubator (STIK) until an appropriate number of colonies grow on the plate.
[0048] 1.2 Shake flask expansion
[0049] The colonies on the plate were inoculated into shake flasks. TSB medium (BD) was used as the shake flask culture medium. The pH was adjusted to 6.5-8. After sterilization and cooling, glucose was added to a concentration of about 3 g / L. The shake flasks were placed in a constant temperature shaking incubator (Minquan) for 5-6 hours.
[0050] 1.3 Fermentation tank culture
[0051] Sterilized tryptic soy casein broth (TSB) was added to the fermenter, the volume of the culture medium was controlled at 40%-80% of the volume of the fermenter, a defoamer (Dow-DF104) was added at a volume ratio of 0.01%-0.05%, the strain was inoculated, the initial OD of the fermentation broth was maintained at 0.05-0.3, the temperature was controlled at 33-39°C, pH 6.5-8, air volume 0.4-2vvm, dissolved oxygen 10%-60%, the rotation speed was linked to the dissolved oxygen, and glucose was added using the fermenter's feed peristaltic pump. The glucose in the fermenter was adjusted to be in two different concentration ranges in two stages by changing the pump speed of the peristaltic pump.
[0052] 1.4 Seed tank culture
[0053] When the culture volume reaches a fermentation scale of more than 150L, the amount of seeds in the shake flask culture is difficult to meet the initial inoculation OD value of the fermentation. Therefore, after completing 1.1 and 1.2, the shake flask seeds harvested in 1.2 need to be inoculated into a small-scale seed tank (e.g., 15L, 50L, 100L, etc.) for culture. The culture method is the same as 1.3, but only 4-5h of culture is required, and only the glucose concentration needs to be controlled at the first stage (that is, the pump speed of the peristaltic pump does not need to be changed). After 4-5h of culture, it is inoculated into a larger volume fermenter.
[0054] Example 2: Screening the best sugar supplementation method in a 1L fermenter
[0055] The applicant has found in many fermentation experiences that the sugar consumption of Neisseria meningitidis MC58 or MC58ΔrmpM strains when the initial OD of fermentation is 0.05-0.3 is: about 1.5 g / L for 0-2h, about 2.5 g / L for 2-4h, about 5 g / L for 4-6h, about 8 g / L for 6h-8h, about 6 g / L for 8h-10h, about 3 g / L for 10-12h, about 3 g / L for 12h-14h, and about 2 g / L for 14h-16h.
[0056] According to the sugar consumption of Neisseria meningitidis MC58ΔrmpM strain at different stages and the glucose concentration in the fermentation broth that is desired to be controlled, the feed pump rate is calculated according to the following formula: feed pump rate = [glucose concentration in fermentation broth (g / L) + sugar consumption of strain (g / L)] / glucose preparation concentration (g / L).
[0057] According to 1.1 of Example 1, the activation of the glycerol tube coating plate was completed, according to 1.2, the inoculation shake flask expansion culture was completed, and according to 1.3, the fermentation tank culture was carried out. The initial OD of the fermentation was set to 0.1 in the 1L fermentation tank, and the glucose concentration was adjusted according to the sugar supplementation scheme in Table 1. The specific control parameters were as follows:
[0058] For tank 101, at 0h of fermentation, glucose was poured into the inoculation port at once (volume of glucose poured = (initial volume of fermentation tank × 30) / glucose concentration) to make the glucose concentration in the initial fermentation liquid reach 30g / L, that is, 90mL.
[0059] Tank 102, in order to keep the glucose concentration in the fermentation broth below 1.5g / L (approximately 0.1g / L-1.5g / L), the parameters of the peristaltic pump are set to 15ml / h for 0-2h, 20ml / h for 2-4h, 32.5ml / h for 4-6h, 47.5ml / h for 6h-8h, 37.5ml / h for 8h-10h, 22.5ml / h for 10-12h, 22.5ml / h for 12h-14h, and 17.5ml / h for 14h-16h. The inventors found that when the glucose concentration is lower than 0.1g / L, the credibility of the detection method is reduced. When the detection value is lower than 0.1g / L, the glucose in the fermentation broth has been exhausted, and the glucose exhaustion will cause the bacteria to die and lyse rapidly, so the glucose concentration in the fermentation broth needs to be higher than 0.1g / L.
[0060] The applicant also found that when the initial OD of the fermentation broth was 0.05-0.3, using TSB medium, no matter how large the fermentation tank was or what sugar control strategy was used, the Neisseria meningitidis MC58ΔrmpM strain was always in the logarithmic growth phase 8 hours before the start of fermentation, and 8 hours to 10 hours was the end of the growth phase, and the growth rate of the strain slowed down.
[0061] Tank 103, in order to maintain the glucose concentration in the fermentation broth at about 3.5 g / L (approximately in the range of 2 g / L-5 g / L) before the end of logarithmic growth and reduce it to below 1.5 g / L (approximately in the range of 0.1 g / L-1.5 g / L) after the end of logarithmic growth, the parameters of the peristaltic pump were set to a pump speed of 25 ml / h for 0-2 h, 30 ml / h for 2-4 h, 42.5 ml / h for 4-6 h, 57.5 ml / h for 6 h-8 h, 20 ml / h for 8 h-10 h, 20 ml / h for 10-12 h, 22.5 ml / h for 12 h-14 h, and 17.5 ml / h for 14 h-16 h.
[0062] Tank 104, the glucose concentration in the fermentation broth was maintained at about 7.5 g / L (about 5-10 g / L) before the end of the logarithmic growth phase, and decreased to below 1.5 g / L (about 0.1 g / L-1.5 g / L) after the end of the logarithmic growth phase. The parameters of the peristaltic pump were set to a pump speed of 45 ml / h for 0-2 h, 50 ml / h for 2-4 h, 62.5 ml / h for 4-6 h, 77.5 ml / h for 6 h-8 h, 0 ml / h for 8 h-10 h, 22.5 ml / h for 10-12 h, 22.5 ml / h for 12 h-14 h, and 17.5 ml / h for 14 h-16 h.
[0063] Table 1. Sugar supplementation scheme, OMV yield and nucleic acid residue
[0064]
[0065] After fermentation begins, samples are taken every two hours to measure the fermentation OD value and the glucose content in the fermentation liquid. Figure 1 As shown, it was found that according to the above pump speed, the glucose concentration in tanks 102, 103, and 104 was consistent with the preset concentration. After 16 hours of fermentation, the detected OD was reduced by more than 0.3 compared with 14 hours, indicating that the strain in the fermentation broth began to lyse. At this time, the fermentation broth was harvested. The OMV yield and nucleic acid residue results at the time of harvest are shown in Table 1.
[0066] It can be seen that the best sugar supplementation strategy is to control the glucose concentration to 2-5 g / L before the end of the logarithmic growth phase, and reduce it to below 2 g / L after the end of the logarithmic growth phase. The nucleic acid residue at harvest was 15.13 μg / ml, and the OMV particle concentration was 9.12×10 15 OMV is the main product in the general industry, and the content is required to be higher than 10 14 / L, and the nucleic acid impurity content was below 30μg / ml, indicating that the two-stage sugar supplementation process greatly improved the OMV yield.
[0067] Example 3: Verification of the two-stage sugar control process on a 5L fermenter
[0068] According to 1.1 of Example 1, the activation of the glycerol tube coating plate was completed, according to 1.2, the inoculation shake flask expansion culture was completed, and according to 1.3, the fermentation tank culture was carried out, and the fermentation was carried out for 0-8 hours, and the glucose concentration was controlled at 2-5g / L. The fermentation was carried out for 8 hours until harvest, and the glucose concentration was controlled to be below 2g / L. Figure 2 As shown, the OD measured at 16h harvest was 0.48 lower than that at the previous time point (14h), and the average particle size of OMV detected by NTA was 62nm (as shown in Figure 3 As shown), nucleic acid residue 15.5 μg / ml, OMV particle concentration 7.6×10 15 This means that the two-stage sugar replenishment method is still applicable to 5L tanks.
[0069] Example 4: Verification of the two-stage sugar control process on a 15L fermenter
[0070] According to 1.1 of Example 1, the activation of the glycerol tube coating plate was completed, according to 1.2, the inoculation shake flask expansion culture was completed, and according to 1.3, the fermentation tank culture was carried out, and the fermentation was carried out for 0-8 hours, and the glucose concentration was controlled at 2-5g / L. The fermentation was carried out for 8 hours until the harvest, and the glucose concentration was controlled to be below 2g / L. Figure 4 As shown, the OD measured at 16h harvest was 0.37 lower than that at the previous time point (14h), and the average particle size of OMV was 61nm ( Figure 5 As shown), nucleic acid residue 18.5 μg / ml, OMV particle concentration 7.78×1015 This indicates that the two-stage sugar replenishment method is still applicable to 15L tanks.
[0071] Example 5: Verification of the two-stage sugar control process on a 150L fermenter
[0072] According to 1.1 of Example 1, the activation of the glycerol tube coating plate was completed, according to 1.2, the inoculation shake flask expansion culture was completed, according to 1.4, the seed tank culture was carried out, and then according to 1.3 of Example 1, the fermentation tank culture was carried out, the fermentation was carried out for 0-8 hours, and the glucose concentration was controlled at 2-5g / L. The fermentation was carried out for 8 hours until harvest, and the glucose concentration was controlled to be below 2g / L. Figure 6 As shown, the OD measured at 16h harvest was 0.41 lower than the previous point (14h), and the average OMV particle size was 61nm ( Figure 7 As shown), nucleic acid residue 21.5 μg / ml, OMV particle concentration 8.18×10 15 This indicates that the two-stage sugar replenishment method is still applicable to the 150L tank.
Claims
1. A method for producing bacterial outer membrane vesicles by bacterial fermentation, characterized in that: a) during the fermentation period from the start of bacterial fermentation to the end of the bacterial logarithmic growth phase, the glucose concentration in the fermentation broth is maintained at 2 g / L-5 g / L; b) During the fermentation period after the end of the bacterial logarithmic growth phase, the glucose concentration in the fermentation broth is maintained at 0.1g / L-1.5g / L, The bacterium is meningococcal MC58 with the rmpM gene knocked out. When fermentation begins, the OD value of the bacteria in the fermentation liquid is 0.05-0.
3.
2. The method according to claim 1, characterized in that In step a), the glucose concentration in the fermentation broth is maintained at 3.5 g / L-5 g / L; and in step b), the glucose concentration in the fermentation broth is maintained at 0.1 g / L-1.5 g / L.
3. The method according to claim 1, characterized in that During the fermentation process, glucose is added in the form of flow addition, and the concentration of glucose in the fermentation broth is regulated by adjusting the glucose concentration of the flow addition and / or regulating the pumping speed of the peristaltic pump for the flow addition of glucose.
4. The method according to claim 1, characterized in that: Before the bacterial fermentation begins, the method further comprises one, two or three of the following stages: plate activation of bacteria, shake flask culture, and seed tank culture.
5. The method according to claim 4, characterized in that When the volume of the fermentation tank is below 150 L, before the bacterial fermentation begins, the method further comprises a plate activation bacteria stage and a shake flask culture stage.
6. The method according to claim 4, characterized in that When the volume of the fermentation tank exceeds 150 L, before the bacterial fermentation begins, the method further includes a plate activation bacteria stage, a shake flask culture stage and a seed tank culture stage.
7. The method according to claim 1, characterized in that During the fermentation process, the temperature was controlled at 33-39°C, pH 6.5-8, air volume 0.4-2vvm, and dissolved oxygen 10%-60%.
8. The method according to claim 1, characterized in that The culture medium used in the fermentation is TSB medium or LB medium, and the volume of the culture medium in the fermenter is 40%-80% of the volume of the fermenter.
9. The method according to claim 1, characterized in that During the fermentation period, the glucose concentration and / or bacterial OD value in the fermentation broth were measured every 1-2 hours.
10. The method according to claim 9, characterized in that When the measured bacterial OD value of the fermentation broth is reduced by 0.3 or more compared with the measured highest OD value, the fermentation is stopped and the bacterial outer membrane vesicles are harvested.
11. The method according to claim 1, characterized in that: The fermentation period from the start of bacterial fermentation to the end of the bacterial logarithmic growth phase was 8 hours.
12. The method according to claim 11, characterized in that From the start of bacterial fermentation, the fermentation was stopped at 16 h and the bacterial outer membrane vesicles were harvested.
Citation Information
Patent Citations
Method for increasing yield of outer membrane vesicles (OMVs) of bacteria and application of OMVs of bacteria
CN111454979A
Method for mediating secretion and high yield of lycopene by high-yield outer membrane vesicles
CN116515877A
Separation and purification method of bacterium-derived outer membrane vesicles
CN116948875A
Fermentation process
US20150166948A1
Methods and compositions for improving insulin production and secretion
WO2023076144A1
